© 1995 by Oxford University Press
Journal of the National Cancer Institute, Vol. 87, No. 9, 645-651,
May 3, 1995
© 1995 Oxford University Press
Adjuvant Tamoxifen Therapy for Early Stage Breast Cancer and Second Primary Malignancies
*Oncologic Center, Karolinska Hospital Stockholm, Sweden
Correspondence to: Lars E. Rutqvist, M.D., Ph.D., Oncologic Center, Karolinska Hospital, S-10401 Stockholm, Sweden.
BACKGROUND:: Tamoxifen is being increasingly used for the treatment of breast cancer and is undergoing study for the primary prevention of breast cancer. However, concerns have been raised that the drug may increase the incidence of new primary malignancies, such as endometrial, liver, and colorectal cancers. Purpose: Our goal was to assess the carcinogenic risks associated with long-term use of tamoxifen in women with early stage breast cancer. Methods: The incidence of new primary cancers among 2729 women participants of the Stockholm Trial was determined at a median follow-up of 9 years. In this trial, after primary surgery, postmenopausal patients aged less than 71 years with unilateral invasive breast cancer were randomly allocated to receive either 2 years of adjuvant tamoxifen (40 mg daily) or no adjuvant endocrine therapy. Information on second cancers was obtained by retrospective linkage to the Swedish Cancer Registry. To increase statistical power, a joint analysis of the incidence of endometrial and gastrointestinal cancers was performed in the following three major studies in Scandinavia evaluating adjuvant tamoxifen therapy: the Stockholm Trial, the Danish Breast Cancer Group Trial, and the South-Swedish Trial. These studies included a total of 4914 patients with a median follow-up of 8–9 years. All P values were calculated from two-tailed tests of statistical significance. Results: In the Stockholm Trial, there was a statistically significant (P =.008) reduction in the incidence of second primary cancers in the contralateral breast among the tamoxifen-treated patients. However, there was a nearly sixfold increase in endometrial cancers (P<.001) and a threefold increase in gastrointestinal cancers in the tamoxifen-treated patients. The results of the joint studies showed a statistically significant increase in endometrial cancers among the tamoxifen-treated patients (relative risk [RR] = 4.1; 95% confidence interval [CI] = 1.9–8.9). There was also an excess of gastrointestinal cancers associated with tamoxifen. Most of this excess involved colorectal cancers (RR = 1.9; 95% CI = 1.1–3.3) and stomach cancer (RR = 3.2; 95% CI = 0.9–11.7). There was no substantial increase in any other type of gastrointestinal cancer (e.g., liver cancer) among the tamoxifen-treated patients. Conclusion: The endometrium and gastrointestinal organs may be target sites for tamoxifen-induced carcinogenesis in humans. Implications: The increased incidence of colorectal and stomach cancers reported here should be regarded as tentative until supported by long-term data from a larger number of tamoxifen trials. Also, appropriate surveillance of cancer incidence is warranted for the protection of participants enrolled in current tamoxifen chemoprevention trials. [J Natl Cancer Inst 87: 645–651, 1995]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M.I. Flamini, A.M. Sanchez, L. Goglia, V. Tosi, A.R. Genazzani, and T. Simoncini Differential actions of estrogen and SERMs in regulation of the actin cytoskeleton of endometrial cells Mol. Hum. Reprod., October 1, 2009; 15(10): 675 - 685. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Brown Is tamoxifen a genotoxic carcinogen in women? Mutagenesis, September 1, 2009; 24(5): 391 - 404. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Decensi, C. Robertson, A. Guerrieri-Gonzaga, D. Serrano, M. Cazzaniga, S. Mora, M. Gulisano, H. Johansson, V. Galimberti, E. Cassano, et al. Randomized Double-Blind 2 x 2 Trial of Low-Dose Tamoxifen and Fenretinide for Breast Cancer Prevention in High-Risk Premenopausal Women J. Clin. Oncol., August 10, 2009; 27(23): 3749 - 3756. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Blevins-Primeau, D. Sun, G. Chen, A. K. Sharma, C. J. Gallagher, S. Amin, and P. Lazarus Functional Significance of UDP-Glucuronosyltransferase Variants in the Metabolism of Active Tamoxifen Metabolites Cancer Res., March 1, 2009; 69(5): 1892 - 1900. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. D. Freedman, J. Ahn, L. Hou, J. Lissowska, W. Zatonski, M. Yeager, S. J. Chanock, W. H. Chow, and C. C. Abnet Polymorphisms in estrogen- and androgen-metabolizing genes and the risk of gastric cancer Carcinogenesis, January 1, 2009; 30(1): 71 - 77. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ono, T. Watanabe, C. Shimizu, N. Hiramoto, Y. Goto, K. Yonemori, T. Kouno, M. Ando, K. Tamura, N. Katsumata, et al. Therapy-Related Acute Promyelocytic Leukemia Caused by Hormonal Therapy and Radiation in a Patient with Recurrent Breast Cancer Jpn. J. Clin. Oncol., August 1, 2008; 38(8): 567 - 570. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Schaapveld, O. Visser, M. J. Louwman, E. G.E. de Vries, P. H.B. Willemse, R. Otter, W. T.A. van der Graaf, J.-W. W. Coebergh, and F. E. van Leeuwen Risk of New Primary Nonbreast Cancers After Breast Cancer Treatment: A Dutch Population-Based Study J. Clin. Oncol., March 10, 2008; 26(8): 1239 - 1246. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. D Freedman, W.-H. Chow, Y.-T. Gao, X.-O. Shu, B.-T. Ji, G. Yang, J. H Lubin, H.-L. Li, N. Rothman, W. Zheng, et al. Menstrual and reproductive factors and gastric cancer risk in a large prospective study of women Gut, December 1, 2007; 56(12): 1671 - 1677. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Zheng, D. Sun, A. K. Sharma, G. Chen, S. Amin, and P. Lazarus Elimination of Antiestrogenic Effects of Active Tamoxifen Metabolites by Glucuronidation Drug Metab. Dispos., October 1, 2007; 35(10): 1942 - 1948. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Chu, A. Fyles, E. M. Sellers, D. R. McCready, J. Murphy, T. Pal, and S. A. Narod Association between CYP3A4 genotype and risk of endometrial cancer following tamoxifen use Carcinogenesis, October 1, 2007; 28(10): 2139 - 2142. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Decensi, S. Gandini, D. Serrano, M. Cazzaniga, M. Pizzamiglio, F. Maffini, G. Pelosi, C. Daldoss, U. Omodei, H. Johansson, et al. Randomized Dose-Ranging Trial of Tamoxifen at Low Doses in Hormone Replacement Therapy Users J. Clin. Oncol., September 20, 2007; 25(27): 4201 - 4209. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Brown, E. M. Tompkins, D. J. Boocock, E. A. Martin, P. B. Farmer, K. W. Turteltaub, E. Ubick, D. Hemingway, E. Horner-Glister, and I. N.H. White Tamoxifen Forms DNA Adducts in Human Colon after Administration of a Single [14C]-Labeled Therapeutic Dose Cancer Res., July 15, 2007; 67(14): 6995 - 7002. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W G McCluggage My approach to the interpretation of endometrial biopsies and curettings. J. Clin. Pathol., August 1, 2006; 59(8): 801 - 812. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Wang, E. R. Rayburn, W. Wang, E. R. Kandimalla, S. Agrawal, and R. Zhang Immunomodulatory oligonucleotides as novel therapy for breast cancer: pharmacokinetics, in vitro and in vivo anticancer activity, and potentiation of antibody therapy. Mol. Cancer Ther., August 1, 2006; 5(8): 2106 - 2114. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. S. Daftary and H. S. Taylor Endocrine Regulation of HOX Genes Endocr. Rev., June 1, 2006; 27(4): 331 - 355. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Gerber, A. Krause, T. Reimer, I. Mylonas, J. Makovitzky, G. Kundt, and W. Janni Anastrozole versus Tamoxifen Treatment in Postmenopausal Women with Endocrine-Responsive Breast Cancer and Tamoxifen-Induced Endometrial Pathology Clin. Cancer Res., February 15, 2006; 12(4): 1245 - 1250. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Guerrieri-Gonzaga, C. Robertson, B. Bonanni, D. Serrano, M. Cazzaniga, S. Mora, M. Gulisano, H. Johansson, F. Formelli, M. Intra, et al. Preliminary Results on Safety and Activity of a Randomized, Double-Blind, 2 x 2 Trial of Low-Dose Tamoxifen and Fenretinide for Breast Cancer Prevention in Premenopausal Women J. Clin. Oncol., January 1, 2006; 24(1): 129 - 135. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E Horner-Glister, M Maleki-Dizaji, C J Guerin, S M Johnson, J Styles, and I N H White Influence of oestradiol and tamoxifen on oestrogen receptors-{alpha} and -{beta} protein degradation and non-genomic signalling pathways in uterine and breast carcinoma cells J. Mol. Endocrinol., December 1, 2005; 35(3): 421 - 432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Arpino, H.L. Weiss, G.M. Clark, S.G. Hilsenbeck, and C.K. Osborne Hormone Receptor Status of a Contralateral Breast Cancer Is Independent of the Receptor Status of the First Primary in Patients Not Receiving Adjuvant Tamoxifen J. Clin. Oncol., July 20, 2005; 23(21): 4687 - 4694. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Swerdlow, M. E. Jones, and For the British Tamoxifen Second Cancer Study Grou Tamoxifen Treatment for Breast Cancer and Risk of Endometrial Cancer: A Case-Control Study J Natl Cancer Inst, March 2, 2005; 97(5): 375 - 384. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Lindblad, W. Ye, C. Rubio, and J. Lagergren Estrogen and Risk of Gastric Cancer: A Protective Effect in a Nationwide Cohort Study of Patients with Prostate Cancer in Sweden Cancer Epidemiol. Biomarkers Prev., December 1, 2004; 13(12): 2203 - 2207. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. R. Kisanga, J. Gjerde, A. Guerrieri-Gonzaga, F. Pigatto, A. Pesci-Feltri, C. Robertson, D. Serrano, G. Pelosi, A. Decensi, and E. A. Lien Tamoxifen and Metabolite Concentrations in Serum and Breast Cancer Tissue during Three Dose Regimens in a Randomized Preoperative Trial Clin. Cancer Res., April 1, 2004; 10(7): 2336 - 2343. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C. Coombes, E. Hall, L. J. Gibson, R. Paridaens, J. Jassem, T. Delozier, S. E. Jones, I. Alvarez, G. Bertelli, O. Ortmann, et al. A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer N. Engl. J. Med., March 11, 2004; 350(11): 1081 - 1092. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Curtis, D. M. Freedman, M. E. Sherman, and J. F. Fraumeni Jr. Risk of Malignant Mixed Mullerian Tumors After Tamoxifen Therapy for Breast Cancer J Natl Cancer Inst, January 7, 2004; 96(1): 70 - 74. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Dignam, K. Wieand, K. A. Johnson, B. Fisher, L. Xu, and E. P. Mamounas Obesity, Tamoxifen Use, and Outcomes in Women With Estrogen Receptor-Positive Early-Stage Breast Cancer J Natl Cancer Inst, October 1, 2003; 95(19): 1467 - 1476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. Schild, R. L. Divi, F. A. Beland, M. I. Churchwell, D. R. Doerge, G. Gamboa da Costa, M. M. Marques, and M. C. Poirier Formation of Tamoxifen-DNA Adducts in Multiple Organs of Adult Female Cynomolgus Monkeys Dosed with Tamoxifen for 30 Days Cancer Res., September 15, 2003; 63(18): 5999 - 6003. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Poirier and L. J. Schild The Genotoxicity of Tamoxifen: Extent and Consequences, Kona, Hawaii, January 23, 2003 Mutagenesis, July 1, 2003; 18(4): 395 - 399. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Decensi, C. Robertson, G. Viale, F. Pigatto, H. Johansson, E. R. Kisanga, P. Veronesi, R. Torrisi, M. Cazzaniga, S. Mora, et al. A Randomized Trial of Low-Dose Tamoxifen on Breast Cancer Proliferation and Blood Estrogenic Biomarkers J Natl Cancer Inst, June 4, 2003; 95(11): 779 - 790. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Cohen, C. Potlog-Nahari, J. Shapira, D. Yigael, and R. Tepper Simple Ovarian Cysts in Postmenopausal Patients with Breast Carcinoma Treated with Tamoxifen: Long-term Follow-up Radiology, June 1, 2003; 227(3): 844 - 848. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Maiti and G. Chen Tamoxifen Induction of Aryl Sulfotransferase and Hydroxysteroid Sulfotransferase in Male and Female Rat Liver and Intestine Drug Metab. Dispos., May 1, 2003; 31(5): 637 - 644. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Dudiak Invited Commentary RadioGraphics, January 1, 2003; 23(1): 151 - 155. [Full Text] [PDF]
|
|
|
|
|
|
D. J. Boocock, K. Brown, A. H. Gibbs, E. Sanchez, K. W. Turteltaub, and I. N.H. White Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA Carcinogenesis, November 1, 2002; 23(11): 1897 - 1902. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Yadollahi-Farsani, D. S. Davies, and A. R. Boobis The mutational signature of {alpha}-hydroxytamoxifen at Hprt locus in Chinese hamster cells Carcinogenesis, November 1, 2002; 23(11): 1947 - 1952. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N Kazerouni, C Schairer, H B Friedman, J V Lacey Jr, and M H Greene Family history of breast cancer as a determinant of the risk of developing endometrial cancer: a nationwide cohort study J. Med. Genet., November 1, 2002; 39(11): 826 - 832. [Full Text] [PDF]
|
|
|
|
|
|
T. Bachleitner-Hofmann, B. Pichler-Gebhard, M. Rudas, M. Gnant, S. Taucher, D. Kandioler, E. Janschek, P. Dubsky, S. Roka, E. Sporn, et al. Pattern of Hormone Receptor Status of Secondary Contralateral Breast Cancers in Patients Receiving Adjuvant Tamoxifen Clin. Cancer Res., November 1, 2002; 8(11): 3427 - 3432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Thompson, D. F. Easton, and the Breast Cancer Linkage Consortium Cancer Incidence in BRCA1 Mutation Carriers J Natl Cancer Inst, September 18, 2002; 94(18): 1358 - 1365. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M J E Mourits, K A T. Hoor, A G J van der Zee, P H B Willemse, E G E de Vries, and H Hollema The effects of tamoxifen on proliferation and steroid receptor expression in postmenopausal endometrium J. Clin. Pathol., July 1, 2002; 55(7): 514 - 519. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kasahara, M. Hashiba, T. Harada, and M. Degawa Change in the gene expression of hepatic tamoxifen-metabolizing enzymes during the process of tamoxifen-induced hepatocarcinogenesis in female rats Carcinogenesis, March 1, 2002; 23(3): 491 - 498. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. H. Driggers, J. H. Segars, and D. M. Rubino The Proto-oncoprotein Brx Activates Estrogen Receptor beta by a p38 Mitogen-activated Protein Kinase Pathway J. Biol. Chem., December 7, 2001; 276(50): 46792 - 46797. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Divi, Y. P. Dragan, H. C. Pitot, and M. C. Poirier Immunohistochemical localization and semi-quantitation of hepatic tamoxifen-DNA adducts in rats exposed orally to tamoxifen Carcinogenesis, October 1, 2001; 22(10): 1693 - 1699. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Guerrieri-Gonzaga, L. Baglietto, H. Johansson, B. Bonanni, C. Robertson, M.-T. Sandri, L. Canigiula, C. Lampreda, S. Diani, E. A. Lien, et al. Correlation between Tamoxifen Elimination and Biomarker Recovery in a Primary Prevention Trial Cancer Epidemiol. Biomarkers Prev., September 1, 2001; 10(9): 967 - 970. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Swain Tamoxifen and Contralateral Breast Cancer: the Other Side J Natl Cancer Inst, July 4, 2001; 93(13): 963 - 965. [Full Text] [PDF]
|
|
|
|
|
|
C. L. Shapiro and A. Recht Side Effects of Adjuvant Treatment of Breast Cancer N. Engl. J. Med., June 28, 2001; 344(26): 1997 - 2008. [Full Text] [PDF]
|
|
|
|
|
|
P. W. Fan and J. L. Bolton Bioactivation of Tamoxifen to Metabolite E Quinone Methide: Reaction with Glutathione and DNA Drug Metab. Dispos., June 1, 2001; 29(6): 891 - 896. [Abstract] [Full Text]
|
|
|
|
|
|
D. H. Phillips Understanding the genotoxicity of tamoxifen? Carcinogenesis, June 1, 2001; 22(6): 839 - 849. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Zhong, Z. Lu, T. Abbas, A. Hornia, K. Chatakondu, N. Barile, P. Kaplan, and D. A. Foster Novel Tumor-promoting Property of Tamoxifen Cell Growth Differ., April 1, 2001; 12(4): 187 - 192. [Abstract] [Full Text]
|
|
|
|
|
|
B. Gerber, A. Krause, H. Muller, T. Reimer, T. Kulz, J. Makovitzky, G. Kundt, and K. Friese Effects of Adjuvant Tamoxifen on the Endometrium in Postmenopausal Women With Breast Cancer: A Prospective Long-Term Study Using Transvaginal Ultrasound J. Clin. Oncol., October 20, 2000; 18(20): 3464 - 3470. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Holli, R. Valavaara, G. Blanco, V. Kataja, P. Hietanen, M. Flander, E. Pukkala, and H. Joensuu Safety and Efficacy Results of a Randomized Trial Comparing Adjuvant Toremifene and Tamoxifen in Postmenopausal Patients With Node-Positive Breast Cancer J. Clin. Oncol., October 20, 2000; 18(20): 3487 - 3494. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. U. Buzdar Tamoxifen's Clinical Applications: Old and New Arch Fam Med, September 1, 2000; 9(9): 906 - 912. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Umemoto, Y. Monden, M. Suwa, Y. Kanno, M. Suzuki, C.-X. Lin, Y. Ueyama, Md.A. Momen, A. Ravindernath, S. Shibutani, et al. Identification of hepatic tamoxifen-DNA adducts in mice: {alpha}-(N2-deoxyguanosinyl)tamoxifen and {alpha}-(N2-deoxyguanosinyl)tamoxifen N-oxide Carcinogenesis, September 1, 2000; 21(9): 1737 - 1744. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Shibutani, J. T. Reardon, N. Suzuki, and A. Sancar Excision of Tamoxifen-DNA Adducts by the Human Nucleotide Excision Repair System Cancer Res., May 1, 2000; 60(10): 2607 - 2610. [Abstract] [Full Text]
|
|
|
|
|
|
P. S. Jones, E. Parrott, and I. N. H. White Activation of Transcription by Estrogen Receptor alpha and beta Is Cell Type- and Promoter-dependent J. Biol. Chem., November 5, 1999; 274(45): 32008 - 32014. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Chen, W. Thompson, R. Semenciw, and Y. Mao Epidemiology of Contralateral Breast Cancer Cancer Epidemiol. Biomarkers Prev., October 1, 1999; 8(10): 855 - 861. [Abstract] [Full Text]
|
|
|
|
|
|
A. Decensi, S. Gandini, A. Guerrieri-Gonzaga, H. Johansson, L. Manetti, B. Bonanni, M. T. Sandri, A. Barreca, A. Costa, C. Robertson, et al. Effect of Blood Tamoxifen Concentrations on Surrogate Biomarkers in a Trial of Dose Reduction in Healthy Women J. Clin. Oncol., September 1, 1999; 17(9): 2633 - 2633. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Suh-Burgmann and A. Goodman Surveillance for Endometrial Cancer in Women Receiving Tamoxifen Ann Intern Med, July 20, 1999; 131(2): 127 - 135. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. N.H. White The tamoxifen dilemma Carcinogenesis, July 1, 1999; 20(7): 1153 - 1160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Cosman and R. Lindsay Selective Estrogen Receptor Modulators: Clinical Spectrum Endocr. Rev., June 1, 1999; 20(3): 418 - 434. [Abstract] [Full Text]
|
|
|
|
|
|
R. T. Chlebowski, D. E. Collyar, M. R. Somerfield, and D. G. Pfister American Society of Clinical Oncology Technology Assessment on Breast Cancer Risk Reduction Strategies: Tamoxifen and Raloxifene J. Clin. Oncol., June 1, 1999; 17(6): 1939 - 1939. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Berliere, C. Galant, and J. Donnez Case Report:The potential oncogenic effect of tamoxifen on the endometrium Hum. Reprod., May 1, 1999; 14(5): 1381 - 1383. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Williams Re: Effects of the Antiestrogens Tamoxifen, Toremifene, and ICI 182,780 on Endometrial Cancer Growth J Natl Cancer Inst, April 21, 1999; 91(8): 722 - 722. [Full Text] [PDF]
|
|
|
|
 |
|
 J. I. Macgregor and V. C. Jordan Basic Guide to the Mechanisms of Antiestrogen Action Pharmacol. Rev., June 1, 1998; 50(2): 151 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Miller, R. A. James, J. K. Richer, D. F. Gordon, W. M. Wood, and K. B. Horwitz Progesterone Regulated Expression of Flavin-Containing Monooxygenase 5 by the B-Isoform of Progesterone Receptors: Implications for Tamoxifen Carcinogenicity J. Clin. Endocrinol. Metab., September 1, 1997; 82(9): 2956 - 2961. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Jackson, J. K. Richer, D. L. Bain, G. S. Takimoto, L. Tung, and K. B. Horwitz The Partial Agonist Activity of Antagonist-Occupied Steroid Receptors Is Controlled by a Novel Hinge Domain-Binding Coactivator L7/SPA and the Corepressors N-CoR or SMRT Mol. Endocrinol., June 1, 1997; 11(6): 693 - 705. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. Reckless, J. C. Metcalfe, and D. J. Grainger Tamoxifen Decreases Cholesterol Sevenfold and Abolishes Lipid Lesion Development in Apolipoprotein E Knockout Mice Circulation, March 18, 1997; 95(6): 1542 - 1548. [Abstract] [Full Text]
|
|
|
|
 |
|
 N. Guthrie, A. Gapor, A. F. Chambers, and K. K. Carroll Inhibition of Proliferation of Estrogen Receptor-Negative MDA-MB-435 and -Positive MCF-7 Human Breast Cancer Cells by Palm Oil Tocotrienols and Tamoxifen, Alone and in Combination J. Nutr., March 1, 1997; 127(3): 544 - 544. [Abstract] [Full Text]
|
|
|
|
 |
|
 R D Bulbrook Long term adjuvant therapy for primary breast cancer BMJ, February 17, 1996; 312(7028): 389 - 390. [Full Text]
|
|
|
|
|
|
C. J. Fryer, H. K. Kinyamu, I. Rogatsky, M. J. Garabedian, and T. K. Archer Selective Activation of the Glucocorticoid Receptor by Steroid Antagonists in Human Breast Cancer and Osteosarcoma Cells J. Biol. Chem., June 2, 2000; 275(23): 17771 - 17777. [Abstract] [Full Text] [PDF]
|
|